Clene Inc
CLNN
Company Profile
Business description
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements).
Contact
6550 South Millrock Drive
Suite G50
Salt Lake CityUT84121
USAT: +1 801 676-9695
Sector
Consumer Defensive
Stock type
Defensive
Industry
Packaged Foods
Fiscal Year End
31 December 2025
Employees
85
Stocks News & Analysis
stocks
Signs of a turnaround for undervalued ASX share
Market likes the payoff from early efforts at reining in costs.
stocks
Australia has the highest dividend yields in the world, so why the endless chase for even higher yields?
Ashley Owen explores why investors' insatiable thirst for higher yields leads to unnecessarily complicating their portfolio.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,825.10 | 20.90 | 0.24% |
| CAC 40 | 8,178.54 | 14.43 | 0.18% |
| DAX 40 | 22,513.42 | 98.60 | -0.44% |
| Dow JONES (US) | 44,546.08 | 165.35 | -0.37% |
| FTSE 100 | 8,732.46 | 32.26 | -0.37% |
| HKSE | 22,620.33 | 805.96 | 3.69% |
| NASDAQ | 20,026.77 | 81.13 | 0.41% |
| Nikkei 225 | 39,149.43 | 312.04 | -0.79% |
| NZX 50 Index | 12,989.18 | 83.20 | 0.64% |
| S&P 500 | 6,114.63 | 0.44 | -0.01% |
| S&P/ASX 200 | 8,555.80 | 15.80 | 0.19% |
| SSE Composite Index | 3,346.72 | 14.24 | 0.43% |